Avis Budget Group (CAR) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants David Calabria - Treasurer & SVP, Corporate FinanceJoe Ferraro - President & CEOIzzy Martins - EVP & CFOStephanie Moore - SVP - Equity ResearchJoseph Padua - Product ManagerLizzie Dove - Vice President Equity Research Conference Call Participants John Babcock - AnalystChristopher N. Stathoulopoulos - Senior Equity Research AnalystDan Levy - Senior Equity Research AnalystChris Woronka - Analyst Operator Please note th ...

Novavax (NVAX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Luis Sanay - Vice President of Investor RelationJohn Jacobs - President & CEORuxandra Draghia-Akli - Executive Vice President, Head of Research & DevelopmentJim Kelly - Executive Vice President, Chief Financial Officer and TreasurerMayank Mamtani - Senior Managing DirectorJohn Trizzino - President & COO Conference Call Participants Roger Song - Senior Equity Research AnalystAlec Stranahan - AnalystThomas Shrader - Equity Rese ...

Griffon (GFF) Q2 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Brian Harris - EVP & CFORonald Kramer - Chairman & CEOTrey Grooms - Managing DirectorCollin Verron - DirectorLee Jagoda - Senior Managing DirectorJustin Mechetti - Equity Research AssociateJeffrey Stevenson - Vice President Conference Call Participants Timothy Wojs - Senior Research Analyst Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Griffin Corporation Fiscal Second Quarter twent ...

Autolus Therapeutics (AUTL) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Amanda Cray - Executive Director - IR & External CommunicationsChristian Itin - CEORob Dolski - CFOJames Shin - Director of Biopharma Equity ResearchMatt Phipps - Group Head - BiotechnologyKarina Rabayeva - VP - Biotech Equity ResearchYifan Xu - Senior Associate - Biotechnology Equity Research Conference Call Participants Gil Blum - Senior AnalystYanan Zhu - Analyst Operator Good day, and thank you for standing b ...

Financial Data and Key Metrics Changes - The company reported a combined revenue of $19,800,000 for Hebsado and ChemoSATs in Q1 2025, with Hebsado sales in the U.S. contributing $18,000,000 and ChemoSATs in Europe adding $1,800,000, compared to $2,000,000 and $1,100,000 respectively in Q1 2024 [7][16] - Gross margins improved to 86% in Q1 2025 from 71% in the same period last year [16] - Net income for Q1 2025 was $1,100,000, a significant turnaround from a net loss of $11,100,000 in Q1 2024 [17] - Positive adjusted EBITDA was reported at $7,600,000 compared to an adjusted EBITDA loss of $7,300,000 in Q1 2024 [17] - The company ended the quarter with approximately $59,000,000 in cash and investments and no debt [8][17] Business Line Data and Key Metrics Changes - The U.S. market for Hebsado and ChemoSATs showed strong growth, with a focus on expanding treatment centers, increasing from 17 to 19 active centers [8][9] - The average treatments per center per month were approximately two in Q1, with expectations to remain just under two for the remainder of the year [10][28] Market Data and Key Metrics Changes - The European market for ChemoSATs grew by 29% over the prior quarter to $1,800,000, although it is not expected to be a significant revenue contributor in the short to medium term due to reimbursement pricing challenges [11] - The company is focusing on generating clinical data from European sites, which have over a decade of experience with ChemoSATs [11][44] Company Strategy and Development Direction - The company aims to expand its active treatment centers to 30 by year-end, with a current pace of opening three to five centers per quarter [9][10] - The strategic focus includes leveraging cash from operations to support research and development initiatives for broader patient populations suffering from liver cancer [8][15] - The company is pursuing additional indications for Hepciddo, including metastatic colorectal and breast cancer, with ongoing clinical trials [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a more even distribution of center activations throughout the year, rather than a concentration in the second half [25] - The company anticipates that the ongoing engagement with oncologists and interventional radiologists will drive demand for treatments [15] - Management acknowledged the competitive landscape but emphasized the collaborative nature of information sharing among treatment centers [38] Other Important Information - The company has implemented a patient access program to assist with copay costs and connect patients with treatment centers [10][53] - The company is managing its European operations on a breakeven basis while focusing on generating clinical data [44] Q&A Session Summary Question: Update on center activations - Management indicated that the pace of center activations may be more even throughout the year than previously anticipated, with potential for two to three additional centers in Q2 [25][26] Question: R&D expenses and EBITDA expectations - R&D expenses are expected to increase significantly, with total operating expenses projected to rise by 60% over 2024, while maintaining positive EBITDA for the year [30][31] Question: Frequency of patient treatments - The average frequency of treatments for patients is expected to remain around 4.1, which is a key driver for overall revenue [36] Question: European market growth and reimbursement - Management noted that while European revenues are increasing, reimbursement challenges remain, and they are focusing on generating clinical data before investing more resources [40][44] Question: Companion diagnostics and potential acquisitions - The company is open to exploring companion diagnostics or synergistic products but has not found suitable opportunities yet [70][72]

Fluence Energy (FLNC) Q2 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Lexington May - Head - IRJulian Nebreda - President and CEOAhmed Pasha - SVP & CFOBrian Lee - Vice PresidentDylan Nassano - Vice PresidentChristine Cho - Managing DirectorHannah Velásquez - Senior Associate - Equity Research Conference Call Participants George Gianarikas - Managing Director and Senior AnalystAmeet Thakkar - Energy Transition & Infrastructure AnalystAndrew Percoco - AnalystKashy Harrison - Senior Resear ...

HanesBrands (HBI) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants T.C. Robillard - Chief Investor Relations OfficerStephen Bratspies - Member of Board of Directors & CEOScott Lewis - CFOJay Sole - Managing DirectorPaul Kearney - VP - Equity ResearchBrandon Cheatham - VP Equity Research Conference Call Participants David Swartz - AnalystIke Boruchow - Managing Director: Senior Analyst - Retailing, Specialty Softlines and E-commerce Operator Good day and thank you for standing by. Welcome ...

EPR Properties (EPR) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Brian Moriarty - Senior Vice President of Corporate CommunicationsGreg Silvers - Chairman and CEOGreg Zimmerman - EVP and CIOMark Peterson - Executive VP, CFO & TreasurerAnthony Paolone - Executive DirectorRJ Milligan - Managing DirectorJustin Haasbeek - Senior Associate, Equity ResearchKathryn Graves - Equity Research Scientific AssociateMitch Germain - MD - Real Estate ResearchSpenser Glimcher - Managing Director Conf ...

Mativ (MATV) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Chris Kuepper - Director - IRShruti Singhal - President and CEOGreg Weitzel - CFOLars Kjellberg - Managing Director Conference Call Participants Daniel Harriman - AnalystNone - Analyst Operator Welcome to Mattev's First Quarter twenty twenty five Earnings Conference Call. On the call today from Mattev are Shruti Singhal, Chief Executive Officer Greg Weitzel, Chief Financial Officer and Chris Cooper, Director of Investor Relatio ...

Montrose Environmental Group (MEG) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Adrianne Griffin - SVP - IR & TreasuryVijay Manthripragada - President & CEOAllan Dicks - Chief Financial OfficerTim Mulrooney - Group Head - Global ServicesChris Grenga - Equity Research Associate Conference Call Participants David Ridley-Lane - Analyst Operator Please note this event is being recorded. I would now like to turn the conference over to Adrienne Griffin, Senior Vice President, Investor Relat ...